Galmed Unveils a Breakthrough Cardiac-Targeted LNP Formulation of Aramchol
GLMD sits 45% above its 52-week low of $0.411.
Summary
Galmed announced a breakthrough cardiac-targeted LNP formulation of Aramchol that redirects the drug from the liver to heart tissue, potentially addressing cardiac fibrosis—a major unmet need in heart failure.
Key Events · Product Development and Regulatory · GLMD
-
Novel Cardiac-Targeted Aramchol Formulation
A proprietary LNP formulation of Aramchol has been developed that selectively targets heart tissue, overcoming the traditional formulation's 80–90% liver accumulation.
-
Addressing Major Unmet Need in Heart Failure
Cardiac fibrosis, a key driver of chronic heart failure, caused an estimated 20.5 million deaths globally in 2025, with no approved disease-modifying therapies.
-
Collaboration with Barcode Nanotech
The formulation was developed using Barcode's AI-enabled in vivo screening platform, which can test hundreds of nanoparticle candidates simultaneously for optimal cardiac delivery.
-
Strategic Expansion into Cardiometabolic Disease
This breakthrough supports Galmed's longer-term vision of advancing Aramchol in new formulations for cardiometabolic diseases, complementing its recent Colospan acquisition in GI medtech.
Analysis · GLMD · Life Sciences
A novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor Aramchol has been developed that selectively targets heart tissue—a significant advance over the traditional formulation, which accumulates 80–90% in the liver. This breakthrough, achieved in collaboration with Barcode Nanotech, aims to address cardiac fibrosis, a major driver of chronic heart failure and a leading cause of death globally. For a micro-cap biotech with a market cap under $4 million, the development could be transformative, potentially attracting partnership interest and validating the company's pivot toward broader cardiometabolic applications. No disease-modifying therapies currently exist for this condition, opening a new therapeutic avenue in cardiovascular disease.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLMD was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.41 to $2.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.